Review Article

Redefining Pharmaceuticals Through AI: A New ERA of Accelerated and Intelligent Drug Development

Charugundla Harini*, Kodiganti Pushpa Latha, Satukuri Samanvitha, Kalagiri Bhargavi
Department of Pharmaceutics, Malla Reddy Institute of Pharmaceutical Sciences, Malla Reddy Vishwavidyapeeth (Deemed to be University) Maisammaguda, Dulapally, Post Via Kompally, Secunderabad-500100, Telangana, India.
***Corresponding author's E-mail:** kodigantipushpalatha4842@gmail.com

Received: 02-05-2026; **Revised:** 24-07-2026; **Accepted:** 30-07-2026; **Published online:** 20-08-2026.

ABSTRACT

The process of drug development is notoriously expensive, time-consuming, and fraught with a high probability of failure. In response, artificial intelligence (AI) has emerged as a transformative force within the pharmaceutical sector. This paper examines the multifaceted applications of AI in drug discovery, including its role in designing drug delivery systems, identifying novel therapeutic candidates, and pioneering new AI methodologies. We delve into specific techniques such as machine learning and deep learning, assessing their impact on critical stages like target identification, virtual screening, and denovo drug design4,8In times past creating new medicines was key to improving human health, but it's a very difficult, expensive and slow journey. It usually takes about 12 years and costs $2.6 billion to develop a single new drug. Because of this, the pharmaceutical industry is working hard to find new ways to make drug discovery cheaper and faster. To improve early clinical development, AI automates patient recruitment from health records and enhances trial design with predictive modelling, protocol optimization, and adaptive methods. AI is accelerating medical innovation by applying multicast and network analysis to drug discovery, overcoming the immense time and cost barriers of traditional development. AI helps scientists quickly find the right disease targets, designs new drug molecules in a fraction of the time, and predicts which ideas will fail early on, saving time and money. This has led to a powerful partnership model where small, agile AI companies, who have the specialized technology, team up with large pharmaceutical giants.

Keywords: Machine Learning, Deep Learning , Generative AI , Drug Discovery, Drug Designs, Drug Development.

INTRODUCTION

Artificial intelligence (AI) is the simulation of human intelligence in computers. The computer learns by gathering information, figures out the rules for using it, makes educated guesses or firm decisions, and then adjusts its own thinking to become more accurate.[9] The pharmaceutical industry has long faced a critical paradox, operating at the forefront of chemical and biological science while being constrained by dated and inflexible manufacturing processes.[1-5] Artificial intelligence is now serving as the long-awaited catalyst for change. By enabling a strategic shift to dynamic Continuous Manufacturing and allowing for the creation of powerful "digital twins" to simulate and perfect production, AI is directly addressing these historical limitations.[5]

Ultimately, AI is the essential bridge allowing the pharmaceutical industry to efficiently scale the production of its most advanced and precise therapies.[5] Computational approaches are revolutionizing early-stage drug design by allowing scientists to virtually model and assess a molecule's key attributes such as its effectiveness, side effects, and how the body will process it before any physical lab work begins.[4,8] This "in silico" process. Not only helps in refining molecules to have the best possible characteristics but also significantly reduces the high failure rate of drugs entering preclinical trials. Furthermore, by integrating artificial intelligence researchers can now analyse vast amounts of pharmaceutical data to autonomously discover novel and highly promising drug candidates, moving beyond human-led design to a more automated and data-driven paradigm.[8,10]

METHODS OF AI

MACHINE LEARNING:

Machine Learning (ML) is a field of artificial intelligence where algorithms are trained to learn patterns and relationships from large datasets.

Machine learning in drug discovery generally falls into two categories: supervised and unsupervised learning.[4]

Supervised learning uses labelled data (e.g., compounds with known effects) to train models that can predict the efficacy and potential side effects of new, untested compounds.[4,8]

Unsupervised learning works with unlabelled data to identify hidden patterns, such as clustering genes or chemicals to discover novel drug targets. Common algorithms like random forests, support vector machines (SVMs), and gradient boosting are used to rapidly analyse massive datasets, accelerating the identification of promising drug candidates.

DEEP LEARNING:

Deep learning is revolutionizing drug design by using specialized deep neural networks, such as CNNs and RNNs, to analyse complex molecular data.[4,8]



Figure 1: Machine Learning

CNNs excel at processing 3D molecular structures to predict how effectively a drug will bind to its target, while RNNs Analyse sequential data like protein sequences to forecast interactions and even generate novel molecule designs. A key advantage of this approach is its ability to automate structure activity relationship (SAR) modelling; instead of relying on manually selected features, deep learning models autonomously learn intricate patterns from data to make more precise predictions about a drug's binding affinity, solubility, and stability.[4] Furthermore, which helps identify and eliminate unsafe compounds long before they reach clinical trials. Essentially, deep learning is being used to make drugs safer by predicting their potential toxicity early on. By training models on vast amounts of data linking chemical structures to known toxicity results, these systems can learn to spot subtle patterns that a human might miss. This allows researchers to flag and filter out potentially harmful compounds at the very beginning of the drug discovery process, which in turn reduces the risk of dangerous side effects appearing later in clinical trials .[4,8]

GENERATIVE AI:

Generative AI is fundamentally transforming pharmacy practice by automating complex tasks, reducing errors, and improving patient care across multiple operational and clinical domains.[4,8] Generative AI can streamline clinical pharmacy tasks, but its educational use is unstudied. Meanwhile, advanced AI like GANs are creating synthetic data for medical research and imaging. To advance, the field needs clear benchmarks, transparent models, and strong collaboration between AI and life science experts. Through an iterative adversarial process, the generator learns to produce highly realistic data, which has powerful applications in enhancing medical imaging, creating super-resolution images, and augmenting limited datasets to improve the accuracy of diagnostic tools while helping to preserve patient privacy. [8]

REINFORCEMENT LEARNING:

This treats the process like a game of decisions. An AI agent essentially learns to "play" by making choices like modifying a molecule's structure or adjusting a dosage to achieve the highest possible score, which is defined as maximizing the drug's effectiveness while minimizing its toxicity.[4,8] This allows it to explore a vast range of treatment options to find optimal strategies that human researchers might not have considered. A similar but distinct approach uses Evolutionary Algorithms, which are inspired by natural selection.[4] These algorithms mimic evolution by generating many different molecular structures, "mutating" them slightly, and then having them compete in a "survival of the fittest" contest based on criteria like how well they bind to a target or how "drug-like" their properties are. By desirable characteristics.[4,8]

MOLECULAR FINGERPRINTING:

This method can efficiently search for and discover entirely new drug candidates with highly optimized and is a computational method that transforms complex chemical structures into compact numerical representations, much like a unique barcode for each molecule.[6,8] These "fingerprints" capture essential structural and physicochemical properties, making them invaluable in drug discovery for rapidly comparing and searching millions of compounds, as well as for training machine learning models.[6] Unlike Natural Language Processing (NLP), which interprets human language, molecular fingerprinting decodes the "grammar" of chemistry, such as functional groups and bond patterns, using various techniques like ECFP (which looks at substructures) or 3D fingerprints (which consider molecular shape).[6] While standard tools like RDK make it easy to generate these fingerprints, challenges remain in optimizing them to better predict a molecule's biological effects and improve their success rate in identifying promising new drugs from vast chemical libraries. However, the field still faces challenges in optimizing these fingerprinting methods for diverse sets of molecules and improving their ability to accurately predict biological activity, especially in large-scale screening efforts.[6,8]

NATURAL LANGUAGE PROCESSING (NLP):

NLP is used to mine scientific text for drug discovery. This field has been revolutionized by transformer models (like BERT and GPT), which have now been adapted for biology to create Protein Language Models that can read, understand, and even predict protein structures and functions.[8] Their ability to process sequences in parallel, unlike older RNN architectures, has led to state of-the-art performance in models like BERT, GPT, and T5, driving breakthroughs in text generation and translation.

Table 1: AI Techniques

Technique	Application	Methods	Accuracy
Deep learning	Drug screening	Using interactions between proteins and their corresponding ligands as Deep Tox input values to predict drug toxicity.	Very Accurate
Neural networks	Drug screening	Using a deep learning neural network in order to predict the structures of different proteins.	Very Accurate
Reinforcement learning	Drug screening	Using a machine learning approach to find an inhibitor molecule for a specific protein (DDR1).	Accurate
Neural networks	Drug design	Using artificial neural networks and deep learning in order to predict interactions between drugs and their targets.	Very accurate
Neural networks	Drug design	Using neural networks which were integrated into a neural computer in order to design new small organic molecules.	Highly accurate

This success has been powerfully adapted into computational biology through Protein Language Models (PLMs), which ingeniously treat proteins as "text" composed of an amino acid "alphabet." [4] By training on vast protein databases, these models can now predict protein structures with high accuracy (as exemplified by AlphaFold2), annotate their functions, and even assist in designing entirely new proteins.[4] Despite challenges such as high computational costs and the need for better interpretability, the use of transfer learning from pre-trained models like ESM-2 and the ability to incorporate 3D structural data point toward a future of even more powerful applications, including multimodal analysis and denovo protein design. [4]

GRAPH NEURAL NETWORKS

GNN is a specialized class of deep learning models designed to analyse data structured as a graph of nodes and their connecting edges.[8] They operate through a "message-passing" system, where each node iteratively aggregates information from its neighbours much like understanding a person by looking at their friends, and then their friends-of-friends. This process allows the network to learn rich, context-aware representations of how each node fits into the broader structure. Because of their unique ability to analyse complex, non-grid-like relationships, GNNs are exceptionally effective for applications like mapping influence in social networks, predicting molecular behaviour in drug discovery, and powering sophisticated recommendation systems.[8]

DRUG DISCOVERY

AI-enabled technologies are fundamentally reshaping pharmaceutical product development by tackling its deep-rooted inefficiencies and uncertainties. By leveraging powerful algorithms, companies can now analyse vast biomedical datasets to design novel drug candidates, accurately predict their safety and efficacy (ADMET properties), repurpose existing drugs for new treatments, and optimize the recruitment process for clinical trials.[3,4,8] This data-driven approach, exemplified by start-ups like On Polaris in drug discovery and Genesis Therapeutics in predictive modelling, minimizes human bias and intervention. Ultimately, AI offers the opportunity to transform traditional, often slow and costly, research methods into a more streamlined, predictable, and efficient process for bringing new medicines to patients.[4,8,10]

AI TOWARDS MANUFACTURING:

The pharmaceutical industry is currently facing a critical challenge where research and development costs are soaring while the efficiency of drug improvement programs is declining.[1] This problem is compounded by a massive expansion in digital information that is difficult to effectively analyse. AI presents a powerful solution by offering the computational ability to process these enormous datasets and apply machine learning algorithms to increase productivity and accuracy. As highlighted in the text, AI can be integrated into four main areas of drug discovery drug design, poly pharmacology, drug repurposing, and drug screening.[4,5] The primary goal of this integration is to accurately predict a drug's properties early in the cycle, which can significantly reduce the financial and ethical burden of extensive clinical trials, thereby reforming the entire drug development process to be more efficient and effective.[5]

"Making a drug correctly is just as crucial as discovering it in the first place, as everything from manufacturing to packaging must ensure the final product is safe, pure, and effective. This is where 'advanced manufacturing' comes in, which essentially means using modern technology like AI to make the production process smarter and more reliable. AI acts as a constant, intelligent watchdog on the factory floor, monitoring equipment, predicting failures before they happen, and spotting any tiny deviations in a batch that could lead to huge losses. This isn't just a futuristic idea, either; the FDA has been actively encouraging companies to adopt these technologies for years, knowing it leads to a more dependable and resilient supply chain for the medicines we all rely on." [5,11]

AI has had a significant impact on drug discovery, particularly in the fields of target identification and validation. This procedure aids in the identification of possible biological targets and elucidates their roles in diseases by analyzing the genomic, proteomic, and metabolomic data. After that, it verifies that these targets are directly related to a disease mechanism and that altering the target is probably going to have a therapeutic impact. Lastly, it is crucial for finding possible therapeutic targets. DotML algorithms search through enormous datasets to find the proteins or biological pathways associated with specific diseases, giving researchers vital information for developing new medications.[11]

TARGET IDENTIFICATION:

An ideal target should be safe, effective, drug gable, and able to meet business needs. However, previously unachievable targets are part of new disease treatment modalities.[8,10] Because it guarantees that a molecular target is directly involved in a disease mechanism and that modulating the target is likely to have a therapeutic effect, target validation is an essential step in the drug discovery process.[4,8] Determining the structure–activity relationship, genetically modifying target genes (knockdown or over expression), creating a drug-resistant mutant of the suspected target, utilizing degradation-based tools to predict the target's effects, and keeping an eye on the signalling pathways downstream of the suspected target are some methods of target validation AI has been applied to measure a drug's binding affinity choose and validate targets and predict drug-target interactions.[4,8]

VIRTUAL SCREENING:

Virtual drug screening is a computational method that employs AI to predict the activity of possible drugs. Researchers can quickly test a library of compounds for their ability to bind to and inhibit particular receptor or enzyme targets using this technique.[4,6] AI systems are able to prioritize compounds for additional experimental testing, predict binding affinities, and analyse molecular structures. Molecular docking simulations can also make use of AI methods like RL and Bayesian docking approximations. Predicting a small molecule's (drug candidate's) preferred orientation when it binds to a target protein is known as molecular docking.[4] AI systems are able to investigate the conformational space and forecast the drug's binding affinity to the target protein. Large datasets of known drug-target interactions can be used to train machine learning algorithms for drug design in order to optimize the PR or imagine new drug target pairs. [4,6,8]



Figure 2: Virtual screening

PREDICTION AND DRUG PROPERTIES:

Artificial intelligence (AI) algorithms can predict the solubility, bio-availability, and toxicity of drug candidates. This reduces time and costs by focusing on compounds with a higher chance of success, which optimizes drug development. Predicting drug properties with machine learning algorithms can be done using a database of known compounds. By recognizing patterns and correlations between a compound's chemical structure and its physicochemical properties, these algorithms learn to operate. By predicting the physicochemical properties of new, untested compounds after training, these models aid in the early stages of drug development.[4] As an illustration, ML models have been used to predict solubility, a crucial property for drug candidates. In a similar vein, machine learning algorithms have been used to predict bio-availability, another crucial property for drug candidates. Predicting toxicity is another area where AI has shown promise. ML models have been used to predict compound toxicity based on their chemical structures. These models can help identify compounds that are less likely to be toxic in the early stages of drug discovery, thereby reducing the risk of harm to humans during the testing phase. [4,8]

REPOSITING OF DRUGS:

High-dimensional biological data is analyzed by AI algorithms to find possible synergistic drug combinations.[3] AI can forecast drug combinations with improved therapeutic effects and fewer side effects by investigating interactions between drugs and their targets. AI can maximize a drug's effectiveness and minimize its side effects by optimizing its dosage and scheduling within a combination.[3,8]

This adjustment makes the combination a more practical treatment option by guaranteeing that its therapeutic benefits are fully realized. Based on individual molecular profiles and disease characteristics, AI-driven precision medicine enables the identification of drug combinations tailored to each patient. The goal of this individualized approach is to reduce the likelihood of drug resistance and improve treatment outcomes. By anticipating possible negative interactions between medications in a combination, AI models can protect patients and prevent potential harm. [8]

DRUG DESIGNING

AI IN DRUG DESIGN:

AI is now involved in every single step of creating a new medicine. Instead of just searching through old drug recipes, scientists can use AI to design completely new molecules from scratch.[4,10] Once they have a promising drug, AI helps figure out the perfect formula to make it effective.which saves a massive amount of time and material. It’s really about using AI to take an idea all the way from a computer screen to a finished product faster and more efficiently than ever before.[5] This iterative process of designing the 3D structures of the receptors to create a new molecule is called denovo drug designing and is aimed at generating new dynamics. Researchers used the indolent space representation to create a model based on the quantitative prediction of drug likeness and drug similarity scores, and the manufactured availability score and synthetic accessibility score.[4,8]

AI IN POLY PHARMACOLOGY:

Poly pharmacology and medication development. They talk about how drug-protein interactions can be predicted and safer drug molecules can be created using AI. Comprehending poly pharmacology is essential for creating medications that minimize off target effects while being effective against several targets. conventional method of designing formulations through trial and error. Quantitative structure-relationship (QSPR) models and decision-support tools are examples of computational tools that can be used to address formulation design problems like porosity, stability, and dissolution. Additionally, pharmaceutical product production can be accelerated by combining AI with mathematical models such as computational fluid dynamics (CFD).[4,5,8]

AI IN CHEMICAL SYNTHESIS:

AI in drug chemical synthesis highlighted the use [application, role, purpose, advantage, benefit, aid, utility, help] of artificial intelligence and ML in drug chemical synthesis. They explore the application [use, role, purpose, advantage, benefit, aid, utility, help] of DL models [designs, patterns] in denovo drug design, the prediction [projection, forecast] of reaction outcomes, and the optimization of synthetic routes. The integration [incorporation, inclusion] of AI with chemical knowledge and data-driven approaches [techniques] has the potential [capacity, capability] to accelerate the drug discovery process [procedure] and facilitate [enable] the design formulation, creation, preparation] of new drug molecules.[8,10]

AI IN DRUG SCREENING:

Screening and drug detection. They highlight the use of AI algorithms to identify novel compounds, predict protein structures, and develop new therapeutic candidates. When AI is integrated into drug screening processes, the drug discovery pipeline can be optimized and potential drug candidates can be discovered more rapidly.[4,8]



Figure 3: AI in chemical synthesis

Table 2: AI in Drug Screening

Topic	Definition	Challenges in Drug Discovery
Generative Adversarial Networks (GANs)	GANs consist of two neural networks: a generator, which creates new molecular structures, and a discriminator, which evaluates these structures for drug- like properties.	- Ensuring generated molecules are chemically valid and synthesizable. - Training requires large datasets of molecular interactions to improve accuracy.
Variational Auto encoders(VAEs)	VAEs are generative models that encode molecular data into a latent space and decode new molecules from this space, exploring chemical variations and optimizing lead compounds.	The quality of the latent space heavily influences the diversity of generated molecules. Difficulty in generating highly diverse chemical libraries.
Reinforcement Learning (RL)	RL involves an agent that explores the chemical space, receiving rewards for actions that improve drug-like properties such as binding affinity, solubility, and toxicity.	Defining effective reward functions to balance multiple objectives. High computational resources are required for effective training and exploration.
Convolutional ral Networks (CNNs)	CNNs are deep learning models that use convolutional layers to extract spatial features from data, often used to predict binding affinities and interactions between ligands and proteins.	- CNNs require large, high- quality 3D molecular datasets to train effectively.- Balancing speed and accuracy in large-scale virtual screening.
Combination of GANs, RL, and CNNs	Combining GANs to generate novel molecules, CNNs to assess protein-ligand interactions, and RL drug candidates optimizes multiple properties novo drug design.	Integrating these models requires large datasets and computational power. – Balancing multiple objectives, such as efficacy, safety ,and synthesizability.

DRUG DEVELOPMENT

There are many obstacles in the way of integrating AI tools into current drug development processes. Rigid protocols and a strong emphasis on established methodologies are common characteristics of traditional pharmaceutical workflows. The current infrastructure, workflows, and expertise may need to be significantly altered in order to integrate AI.[5] Adoption of these technologies may also be hampered by worries about data privacy, intellectual property, and the possible effects of AI on employment in the pharmaceutical sector. AI-enabled technologies have developed into adaptable tools that can be used in a variety of stages of product development, including the design of new drugs, formulation development, drug re-purposing improving R&D efficacy, aggregating and analyzing bio-medicine data, and optimizing the decision-making process to recruit study participants in clinical trials.[4,8] The goal of pharmaceutical development is to create a high-quality product as well as a manufacturing process that ensures consistent production. These prospective AI applications provide the chance to minimize bias and human intervention while addressing the inefficiencies and uncertainties that arise in conventional product development methods. Product development uses a variety of AI algorithms.[8]

In order to lower the financial expenses and possible losses associated with virtual screening, pharmaceutical companies are switching to AI solutions. The AI market increased from USD 200 to USD 700 million between 2015 and 2018, and it is projected to reach USD 5 billion by 2024. AI may change the pharmaceutical and medical industries, with a projected 40% increase between 2017 and 2024. In addition to working with AI service providers to develop vital medical equipment, numerous pharmaceutical companies have made investments in AI or are still doing so.[5,8]

AI IN MARKET POSITION

Market alignment is a crucial part of most business strategies for companies looking to carve out a new niche for themselves. It is the plan of making the marketed product unique in order to persuade consumers to buy it . The marketing company used this tactic to promote the premium brand Viagra, focusing on both men's erectile dysfunction and related problems that affected their quality of life. By using technology and e-commerce as a springboard, it has become easier for businesses to gain an innate recognition of their brand identity in the public eye. According to the "Internet Advertising Bureau," businesses use search engines, one of the many technological resources at their disposal, to gain a prominent position in online marketing and support product alignment. Businesses constantly try to categorize their websites more.[9]

AI IN MARKET FORECASTING & SCRUTINY

A company's continued development and expansion of its business interests is essential to its success. The pharmaceutical industry's R&D harvest is decreasing despite enormous financial investments because businesses are unable to adjust to modern marketing strategies. Through a multimodal decision-making scheme that gathers and assesses statistical and mathematical data and performs human interpretations to enable AI-enabled decision-making paradigms search for new marketing opportunities, the development of digital technologies, dubbed the "Fourth Industrial Revolution," is enabling innovative.



Figure 4: AI in market forecasting & scrutiny

Digitalized marketing.[9] AI also makes it easier to thoroughly examine a product's essential features from the perspective of the consumer and to understand market demands, which aids in decision-making through the use of prediction models. Additionally, this method can forecast sales and assess the market. AI-engaging software employs users and creates knowledge among them.[9]

AI IN PRODUCT COST:

The organization determines the final cost of the product based on the evaluation of the market and the expenses incurred in the development of pharmaceutical products. Using AI's ability to mimic a human expert's thought process to assess the factors that determine a product's value after it has been produced is a key idea in using AI to reduce this expense .[9] The cost of both branded and generic medications is determined by a number of factors, including the cost of the reference item, price-determining statutes, the duration of the exclusivity period, the market stake of the improvised agent after a year before the patent expires, and the financial outlay in the course of research and advancement of the medication . The algorithm in machine learning (ML) evaluates vast amounts of statistical data, such as product advancement expenditures, product needs in the market, itemization record expenses, manufacturing expenses, and competitors' product costs.[9]

ADVANCE TECHNICS IN DEVELOPMENT:

The pharmaceutical industry is leveraging sophisticated technologies like "in silico ADMET" and block chain to revolutionize both drug discovery and supply chain integrity. In silico ADMET acts as a predictive tool, using either highly specific protein simulations or broad, AI powered analysis of large datasets to forecast how a potential drug will behave in the human body, thereby weeding out non-viable candidates early in the process. Complementing this, block chain technology provides a secure and transparent digital ledger for the entire manufacturing and distribution journey; its unchangeable and decentralized nature ensures the authenticity of medicines and prevents counterfeiting.[4,5] While ADMET models are demanding in terms of data and precision, and block chain is currently limited by its high cost and the need for specialized expertise, both represent a significant shift towards a more technologically advanced, efficient, and safer pharmaceutical landscape. [5,8]

TRANSPARENCY DEVELOPMENT:

Drug companies operate on incredibly strict, by-the-book protocols for safety, but AI is the complete opposite it's designed to learn and change.

Table 3: AI in Drug Developments

Area	Applications	Limitations
1.Patient Recruitment and Site Selection	AI algorithms evaluate EHRs to quickly assess patient eligibility, ensuring suitable candidates are screened for trials.	Relies on access to high quality, standardized EHRs. Privacy concerns and potential biases in the data can affect recruitment accuracy.
2.Predictive Modeling for Trial Outcomes	AI simulates different trial designs, including dose escalation in early clinical studies and prediction of toxicity, using historical data, trial parameters, and patient characteristics. Predictive models focus on trial designs with the highest likelihood of success.	Predictions may not fully capture real-world complexities. Dependence on historical data may limit generalise ability for novel treatments.
3.Protocol Optimization	AI tools simulate different trial scenarios, optimizing protocols by adjusting variables like dosage, treatment duration, and patient characteristics.	Optimization outcomes are only as good as the input data and models. Over-reliance on AI could overlook nuanced clinical or ethical considerations.
4.Adaptive Trial Designs	Enables ongoing data analysis to make real-time modifications to trials, such as adjusting dosages or patient cohorts based on interim results. Supports DCTs by facilitating remote monitoring, virtual visits, and digital data collection.	Real-time adjustments require robust infrastructure and regulatory approval processes. Decentralized trials depend on patient access to reliable digital technology.
5.Synthetic Control Arms (SCAs)	Uses RWD and historical trial data to simulate control arms**,** Reducing the need for placebo groups. Addresses ethical, logistical, and cost challenges in traditional trials.	SCAs depend on high-quality, well annotated datasets Historical data may not fully represent the current trial population. Regulatory acceptance is still evolving.
6. Digital Twins	Creates digital replicas of patients, allowing virtual testing of treatments before application. Reduces risks and optimizes therapeutic strategies.	Developing accurate digital twins is complex and computationally intensive. Requires detailed patient data, raising privacy and data-sharing concerns.

That fundamental clash is a massive hurdle. On top of that, these companies guard their research data like gold, so they're naturally terrified of handing it over to a new system. And you can't ignore the human element; there's a real fear that "AI" is just another term for "layoffs," and you often have a culture clash between the old-guard scientists and the new data experts. Honestly, navigating the corporate culture and getting people on board is a much bigger challenge than just building the AI itself.[5,8]

APPLICATIONS OF AI

AI as the Inventor: Instead of just testing existing molecules, these AI systems (RNNs, GANs, etc.) are acting like incredibly creative chemists, dreaming up completely novel molecules from scratch (denovo design).[4]

AI as the Quality Control: They aren't just creating random designs. They're specifically building them to have the right properties to be effective against a disease ("bioactivity") but not poisonous to the patient ("toxicity"). [4,8]

AI as the Master Builder: Tools like Diff Dock and ESM-2 are the specialized power tools. They figure out exactly how the drug "key" will fit into the disease's "lock" (protein ligand docking) and even help design the key itself. Companies like Atom wise and Benevolent AI are the ones putting this all together into a fully fledged platform, proving it works in these incredibly powerful new systems that can dream up new medicines.[4,5] But on the other side, you have the actual scientists in the labs. They've built their entire careers on expertise, intuition, and a deep understanding of chemistry. Now they're being asked to bet the farm on a "black box" algorithm they can't fully see inside, and it's creating a serious crisis of trust. It's the desperate need for a faster, cheaper future crashing right into the human need to truly understand and believe in the tools you're using.[5] This rule forces developers to rigorously analyse a drug's dose, efficacy, and toxicity profile far earlier in the pipeline. This, in turn, creates a perfect, non-threatening role for AI not as a competitor, but as a powerful analytical tool. By helping human scientists make sense of this complex data, the AI becomes an essential partner that augments their expertise rather than attempting to replace it, potentially offering a practical truce in the cultural clash between traditional R&D and machine-driven methods.[4,8]



Figure 5: Applications of AI

RESULT AND DISCUSSION

FUTURE PROSPECTS:

The principal promise of artificial intelligence in the pharmaceutical industry resides in its potential to reduce costs and improve efficiency. Comprehensive research indicates that dynamic learning can yield exceptionally accurate AI models while requiring only half as much data or even less than conventional AI approaches and data sampling methods. While the specific factors contributing to this heightened effectiveness are not entirely understood, it appears that reducing redundancy and bias, as well as obtaining more substantial data to better navigate decision boundaries, significantly contributes to this improved performance. [4,8]

Therefore, despite the expected technical overhead that may accompany the implementation of dynamic learning strategies, screening costs could potentially be decreased by as much as 90%. AI technology's exceptional data-extraction capabilities have elevated computer assisted medication planning to a new level of significance that takes into account a variety of clinical factors outperforming the efficacy of fragmented information and expediting prescription procedures. AI technology has the potential to revolutionize many aspects of drug discovery and development, possibly becoming the norm for computer-assisted medication planning techniques as clinical data continues to grow and AI algorithms advance. The ultimate goal of using AI in this context is to shorten drug development cycles, reduce costs and increase success rates all of which will be made possible by such developments.[8]

AI's primary potential in the pharmaceutical sector is to lower expenses and boost productivity. Numerous studies have shown that, in comparison to conventional AI and information sub sampling techniques, dynamic learning can identify extremely accurate AI models with half or less information. Reduced repetition and predisposition, as well as obtaining more important information to overcome choice limits, seem to be important factors in this improved execution, even though the exact cause of this increased productivity is still unknown. Writing business applications has benefited from machine learning techniques' ability to handle complex analyses with large, heterogeneous, and high dimensional information collections without the need for manual input. integrating machine learning, especially deep learning.[4,5,10]

CURRENT CHALLENGES:

There are still many challenges in the implementation and integration of these technologies into the drug discovery process specifically and the pharmaceutical industry in general. The first challenge is inefficient data integration, which is caused by diversity between datasets, which may include raw data, processed data, metadata, or candidate data, that must be collected and collated for effective analysis, but currently, there is no method of doing so, and without the right kind of data, the output of the machine learning algorithms will be incorrect.[5,8] Therefore, there is a need for more efficient methods of integrating available data into data banks before the drug discovery process starts.

A second challenge is occupational and skill set immobility: the majority of workers in the pharmaceutical industry do not have the skills or qualifications to operate AI systems, and few have the right combination of skills in data science and molecular chemistry and biology to apply AI in a pharmaceutical context, requiring a knowledge of the underlying chemistry to generate appropriate algorithms and vice versa.[5]

A third, but related, challenge is skeptics about machine learning and AI in the pharmaceutical industry, due to a lack of understanding of the method of algorithms, the so-called "black box" phenomenon, and a lack of trust in the results produced.[5] Skeptics may not want to use the data produced with AI and machine learning, thus wasting time and money and hindering the industry in terms of efficiency .Another problem with distrust of AI is that it can create a sense of fear. [5,8]

CONCLUSION

This review demonstrated how incorporating AI can transform drug development and discovery.[4,8] AI can speed up target identification; optimize lead compounds, and forecast pharmacokinetics and toxicity by using machine learning algorithms, deep learning techniques, and data analytics. This review highlighted the need for strong validation and ethical considerations in AI-driven drug development by recognizing the inherent difficulties, such as inadequate resources and model interpretability on a larger scale.[1,4,10] However, the future shows how urgently industry stakeholders and the research community must work together to overcome these obstacles and fully utilize AI's potential to spur innovation and enhance patient outcomes in medical research.[3,4,10] It's critical to stay conscious of the risks and constraints of AI technology. Reducing reliance on supercomputing power, addressing ethical issues related to data collection, and deploying AI in the healthcare industry in a controlled way to minimize adverse effects are all areas where AI technology can be improved. The creation of a virtual human with full complexity, which would enable precise predictions of all potential interactions between molecules and the investigation of all therapeutic potentials and unfavourable side effects, may be the key to the future of AI-assisted drug discovery. [4,8,10]

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFFERENCES

1. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
2. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40–51.
3. Xue H, Li J, Xie H, Wang Y. Review of drug repositioning approaches and resources. Int J Biol Sci. 2018;14(10):1232–1244.
4. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. In: Hock FJ, Pugsley MK, editors. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Cham: Springer International Publishing; 2024. p. 1461–1498.
5. Vora LK, Donnelly RF, et al. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023;15(7):1916.
6. Lavecchia A, Di Giovanni C. Virtual screening strategies in drug discovery: a critical review. Curr Med Chem. 2013;20(23):2839–2860.
7. Kaur T, Diwakar A, Mirpuri P, Tripathi M, Chandra PS, Gandhi TK. Artificial intelligence in epilepsy. Neurol India. 2021;69(3):560–566.
8. Blanco-González A, Cabezón A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro Á, et al. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals (Basel). 2023;16(6):891.
9. Malik P, Pathania M, Rathaur VK. Overview of artificial intelligence in medicine. J Fam Med Prim Care. 2019;8(7):2328–2331.

10. Hinkson IV, Madej B, Stahlberg EA. Accelerating therapeutics for opportunities in medicine: a paradigm shift in drug discovery. Front Pharmacol. 2020;11:770.

11. Barker R. A flexible blueprint for the future of drug development. Lancet. 2010;375(9712):357–359.

12. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it. Acta Pharm Sin B. 2022;12(7):3049–3062.

For any questions related to this article, please reach us at: globalresearchonline@rediffmail.com
New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com